Free Trial
NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

$39.52
+1.24 (+3.24%)
(As of 08/21/2024 ET)
Today's Range
$37.57
$39.88
50-Day Range
$33.22
$41.91
52-Week Range
$18.00
$53.92
Volume
760,538 shs
Average Volume
973,331 shs
Market Capitalization
$2.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.83

SpringWorks Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
74.2% Upside
$68.83 Price Target
Short Interest
Bearish
15.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.34) to ($1.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.85 out of 5 stars

Medical Sector

834th out of 924 stocks

Biological Products, Except Diagnostic Industry

132nd out of 145 stocks

SWTX stock logo

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Stock Price History

SWTX Stock News Headlines

This technology could swing the election
Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.
This technology could swing the election
Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.
See More Headlines
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2024
Today
8/21/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SWTX
Fax
N/A
Employees
230
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$68.83
High Stock Price Target
$75.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+74.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-325,100,000.00
Pretax Margin
-349.32%

Debt

Sales & Book Value

Annual Sales
$86.19 million
Book Value
$10.01 per share

Miscellaneous

Free Float
68,448,000
Market Cap
$2.93 billion
Optionable
Optionable
Beta
0.78

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Francis I. Perier Jr. (Age 64)
    M.B.A., Chief Financial Officer
    Comp: $768.24k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Chief Operating Officer
    Comp: $1.02M
  • Dr. James Cassidy M.D. (Age 64)
    Ph.D., Chief Medical Officer
    Comp: $904.25k
  • Mr. Michael P. Nofi (Age 53)
    Chief Accounting Officer
  • Mr. Tai-An Lin Ph.D.
    Chief Scientific Officer
  • Ms. Kim Diamond
    Vice President of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 67)
    General Counsel & Secretary
    Comp: $568.64k
  • Mr. Daniel J. PichlMr. Daniel J. Pichl (Age 40)
    Chief People Officer
    Comp: $428.51k
  • Mr. Bhavesh Ashar M.B.A. (Age 58)
    Chief Commercial Officer
    Comp: $729.62k

SWTX Stock Analysis - Frequently Asked Questions

How have SWTX shares performed this year?

SpringWorks Therapeutics' stock was trading at $36.50 on January 1st, 2024. Since then, SWTX shares have increased by 8.3% and is now trading at $39.52.
View the best growth stocks for 2024 here
.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. SpringWorks Therapeutics's quarterly revenue was up 59732900.0% compared to the same quarter last year.

Does SpringWorks Therapeutics have any subsidiaries?

The following companies are subsidiaries of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

Top institutional investors of SpringWorks Therapeutics include Maverick Capital Ltd. (3.50%), Marshall Wace LLP (3.14%), Perceptive Advisors LLC (2.23%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Orbimed Advisors Llc, Daniel Pichl, Julie Hambleton, Saqib Islam and L Mary Smith.
View institutional ownership trends
.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN) and Alnylam Pharmaceuticals (ALNY).

This page (NASDAQ:SWTX) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners